Skip to main content
Clinical Trials/JPRN-jRCTs071200013
JPRN-jRCTs071200013
Recruiting
Phase 2

Multicenter interventional study of preventive effects of RINDERON-V Ointment 0.12% for severe oral mucositis during radiotherapy for oral cavity and oropharynx tumor

Soutome Sakiko0 sites102 target enrollmentMay 11, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Oral cavity and oropharynx tumor
Sponsor
Soutome Sakiko
Enrollment
102
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 11, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Soutome Sakiko

Eligibility Criteria

Inclusion Criteria

  • 1\. Patients with oral cavity and oropharynx tumor undergoing platinum plus IMRT or cetuximab plus IMRT
  • 2\. Conventionally fractionated irradiation with 50Gy or more

Exclusion Criteria

  • 1\. Patients with problem in judgement
  • 2\. Patients who are allergic to the drugs used
  • 3\. Women who are or may be pregnant
  • 4\. Oral cavity without the radiation field
  • 5\. In the event that the investigator or research investigator determines that participation in this study is not appropriate

Outcomes

Primary Outcomes

Not specified

Similar Trials